Abstract
Linezolid is the first drug in a new class of synthetic antimicrobials, the oxazolidinones, to be approved by the Food and Drug Administration. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms. We describe 2 patients who developed peripheral neuropathy after prolonged treatment with linezolid. Linezolid-associated peripheral neuropathy has not been well documented. Most reported cases of linezolid-associated peripheral neuropathy have occurred in patients who took linezolid for a period longer than the recommended 28 or fewer days. Health care providers must be alert to the potential for serious adverse effects associated with linezolid use, including peripheral neuropathy.
Original language | English (US) |
---|---|
Pages (from-to) | 927-930 |
Number of pages | 4 |
Journal | Mayo Clinic Proceedings |
Volume | 79 |
Issue number | 7 |
State | Published - 2004 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Linezolid-associated peripheral neuropathy. / Rho, Jennifer P.; Sia, Irene Gaw; Crum, Brian A.; Dekutoski, Mark B.; Trousdale, Robert T.
In: Mayo Clinic Proceedings, Vol. 79, No. 7, 2004, p. 927-930.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Linezolid-associated peripheral neuropathy
AU - Rho, Jennifer P.
AU - Sia, Irene Gaw
AU - Crum, Brian A.
AU - Dekutoski, Mark B.
AU - Trousdale, Robert T.
PY - 2004
Y1 - 2004
N2 - Linezolid is the first drug in a new class of synthetic antimicrobials, the oxazolidinones, to be approved by the Food and Drug Administration. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms. We describe 2 patients who developed peripheral neuropathy after prolonged treatment with linezolid. Linezolid-associated peripheral neuropathy has not been well documented. Most reported cases of linezolid-associated peripheral neuropathy have occurred in patients who took linezolid for a period longer than the recommended 28 or fewer days. Health care providers must be alert to the potential for serious adverse effects associated with linezolid use, including peripheral neuropathy.
AB - Linezolid is the first drug in a new class of synthetic antimicrobials, the oxazolidinones, to be approved by the Food and Drug Administration. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms. We describe 2 patients who developed peripheral neuropathy after prolonged treatment with linezolid. Linezolid-associated peripheral neuropathy has not been well documented. Most reported cases of linezolid-associated peripheral neuropathy have occurred in patients who took linezolid for a period longer than the recommended 28 or fewer days. Health care providers must be alert to the potential for serious adverse effects associated with linezolid use, including peripheral neuropathy.
UR - http://www.scopus.com/inward/record.url?scp=3042856503&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3042856503&partnerID=8YFLogxK
M3 - Article
C2 - 15244392
AN - SCOPUS:3042856503
VL - 79
SP - 927
EP - 930
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
SN - 0025-6196
IS - 7
ER -